Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Shionogi to Acquire 9 Products from Victory Pharma of the US
August 1, 2011
- FDA's Advisory Committee Does Not Recommend Approval of Dapagliflozin
August 1, 2011
- Korosho, PMDA Providing Risk Info on Drugs Under Review on Websites
August 1, 2011
- LTT Bio-Pharma to License Inhalant PC-SOD to CKD in South Korea
August 1, 2011
- Transfer of Part of PMDA Functions to Osaka Proposed in Kansai Sogo Tokku Plan
August 1, 2011
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
- Chugai Applies for Approval of Pulmozyme for Cystic Fibrosis
August 1, 2011
- Mochida, MTPC to Launch Lexapro on Aug. 22
August 1, 2011
- Sodium Phenylbutyrate from CMIC Designated as Orphan Drug
August 1, 2011
- Nihon Chouzai to Introduce Finger Vein Authentication at All Stores
August 1, 2011
- NPhA Withdraws Request to Refrain from Offering Points for Dispensing Services
August 1, 2011
- Ain Pharmaciez to Improve Its Services for Patients Using Smart Phones
August 1, 2011
- Rivaroxaban's Safety Found Non-inferior to Warfarin in Domestic PIII Study
August 1, 2011
- Pfizer Obtains Approval for Generics of 14 APIs
August 1, 2011
- US FDA Announces Draft Guidance for Simultaneous Development of Therapeutics and Companion Diagnostic Devices
August 1, 2011
- Daiichi Sankyo Espha to Deal with Both Long-listed Products, Generics
August 1, 2011
- Biosimilars Optimize Healthcare Costs: JSGM Seminar
August 1, 2011
- AZ, NCC Announce Comprehensive Agreement for Development of Anticancer Drugs
August 1, 2011
- Eisai Obtains Marketing Rights to 2 Drugs from Orion in China
July 25, 2011
- Aricept Generics Approved from 33 Companies
July 25, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…